文献速递基础与转化研究临床试验与 GCP

复发特发性炎性肌炎患者经CD19 CAR T细胞初始及重复治疗后改用BCMA CAR T细胞治疗

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
PubMed 文献 · Nat Med · 2025-04-17

一例45岁女性难治性Jo-1相关抗合成酶综合征患者,经CD19 CAR T细胞治疗获缓解后9个月复发,再次输注同一产品后CAR T细胞未扩增并检出靶向CD19 CAR的T细胞,虽行全剂量淋巴清除仍无临床反应。经抗CD38抗体达雷妥尤单抗桥接后行BCMA CAR T细胞治疗,BCMA CAR T细胞扩增、清除淋巴组织浆细胞、降低自身抗体水平并重新诱导稳定无药缓解。

要点

  • CD19 CAR T细胞再输注后未扩增并检出靶向CD19 CAR的T细胞,全剂量淋巴清除后仍无临床反应。
  • 达雷妥尤单抗桥接有效但持续时间有限。
  • BCMA CAR T细胞治疗使浆细胞清除、自身抗体下降并重新诱导稳定无药缓解。

核心结论

  • 本病例凸显CAR T细胞再输注的挑战及替代靶点与产品的潜力,并提示清除浆细胞可能改善难治患者的治疗结局。

研究设计与样本

  • 病例报告:一例45岁女性难治性Jo-1相关抗合成酶综合征患者。

主要发现

  • CD19 CAR T细胞治疗后初始获疾病缓解,9个月后疾病复发。
  • 再次输注同一产品后CAR T细胞未扩增,并检出靶向CD19 CAR的T细胞。
  • 全剂量淋巴清除后未观察到临床反应。
  • 抗CD38抗体达雷妥尤单抗桥接有效但持续时间有限。
  • BCMA CAR T细胞扩增,清除淋巴组织浆细胞,降低自身抗体水平并重新诱导稳定无药缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19 chimeric antigen receptor (CD19 CAR) T cell therapy has been shown to induce stable drug-free remission in patients with refractory autoimmune disease. The management of potential relapses is currently unclear. Here we report on a 45-year-old woman with treatment-refractory Jo-1-associated anti-synthetase syndrome, who initially achieved disease remission after CD19 CAR T cell therapy but then experienced disease relapse after 9 months. After reinfusion of the same product, CAR T cells failed to expand and T cells targeting the CD19 CAR were detected. Despite full-dose lymphodepletion, no clinical response was observed. After bridging with anti-CD38 antibody daratumumab, which was efficacious with limited durability, plasma-cell-targeting B-cell maturation antigen (BCMA) CAR T cell therapy was performed. BCMA CAR T cells expanded, cleared plasma cells in lymphoid tissue, reduced autoantibody levels and re-induced stable drug-free remission. This case highlights the challenges in CAR T cell reinfusion, the potential of alternative targets and products, and suggests that the depletion of plasma cells may enhance therapeutic outcomes in patients who become treatment-refractory.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Müller F, Wirsching A, Hagen M, et al. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med. 2025. PMID: 40245922. doi:10.1038/s41591-025-03718-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。